Global Factor Xa Inhibitors Market Growth 2026-2032
The global Factor Xa Inhibitors market size is predicted to grow from US$ 24030 million in 2025 to US$ 35890 million in 2032; it is expected to grow at a CAGR of 6.0% from 2026 to 2032.
Factor Xa inhibitors are anticoagulant drugs that block factor Xa, an enzyme crucial in the blood clotting process, thereby preventing clot formation. They are used to treat and prevent conditions like deep vein thrombosis, pulmonary embolism, and atrial fibrillation.
The market for Factor Xa inhibitors has been expanding steadily due to their advantages over traditional anticoagulants. Drugs like rivaroxaban, apixaban, and edoxaban are increasingly preferred for their ease of use, predictable dosing, and minimal need for routine monitoring. This shift has been driven by the need for more convenient and effective treatments for conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF).
Competition in the Factor Xa inhibitors market is growing as pharmaceutical companies continue to develop and launch new products with improved formulations. Efforts are focused on expanding the indications of these drugs, optimizing dosing regimens, and enhancing patient adherence. This competitive landscape is fostering innovation and leading to a wider range of options available to healthcare providers and patients.
However, the market faces challenges including high drug costs and the introduction of alternative therapies. Regulatory scrutiny and evolving treatment guidelines also impact market dynamics. Despite these challenges, ongoing advancements and research are expected to drive continued growth and development in the Factor Xa inhibitors market.
LP Information, Inc. (LPI) ' newest research report, the “Factor Xa Inhibitors Industry Forecast” looks at past sales and reviews total world Factor Xa Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected Factor Xa Inhibitors sales for 2026 through 2032. With Factor Xa Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Factor Xa Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Factor Xa Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Factor Xa Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Factor Xa Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Factor Xa Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Factor Xa Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Factor Xa Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Factor Xa inhibitors are anticoagulant drugs that block factor Xa, an enzyme crucial in the blood clotting process, thereby preventing clot formation. They are used to treat and prevent conditions like deep vein thrombosis, pulmonary embolism, and atrial fibrillation.
The market for Factor Xa inhibitors has been expanding steadily due to their advantages over traditional anticoagulants. Drugs like rivaroxaban, apixaban, and edoxaban are increasingly preferred for their ease of use, predictable dosing, and minimal need for routine monitoring. This shift has been driven by the need for more convenient and effective treatments for conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF).
Competition in the Factor Xa inhibitors market is growing as pharmaceutical companies continue to develop and launch new products with improved formulations. Efforts are focused on expanding the indications of these drugs, optimizing dosing regimens, and enhancing patient adherence. This competitive landscape is fostering innovation and leading to a wider range of options available to healthcare providers and patients.
However, the market faces challenges including high drug costs and the introduction of alternative therapies. Regulatory scrutiny and evolving treatment guidelines also impact market dynamics. Despite these challenges, ongoing advancements and research are expected to drive continued growth and development in the Factor Xa inhibitors market.
LP Information, Inc. (LPI) ' newest research report, the “Factor Xa Inhibitors Industry Forecast” looks at past sales and reviews total world Factor Xa Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected Factor Xa Inhibitors sales for 2026 through 2032. With Factor Xa Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Factor Xa Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Factor Xa Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Factor Xa Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Factor Xa Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Factor Xa Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Factor Xa Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Factor Xa Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Oral Drugs
- Injections
- Deep Vein Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Bristol Myers Squibb
- Daiichi Sankyo
- Janssen Pharmaceuticals
- Bayer
- Viatris
- Dr. Reddy's Laboratories
- GlaxoSmithKline
- Eugia Pharma
- Accord Healthcare
- Apotex
- Zydus
- Lupin
- Jiangsu Hengrui Pharmaceuticals
- Cspc Ouyi Pharmaceutical
- Zhejiang Hisun Pharmaceutical
- Hansoh Pharma
- Chia Tai Tianqing Pharmaceutical
- Shanghai Huilun Pharmaceutical
- Qilu Pharmaceutical
- HEC Pharma
- BrightGene
- Kelun Pharmaceutical
- Nanjing King-Friend Biochemical Pharmaceutical
- What is the 10-year outlook for the global Factor Xa Inhibitors market?
- What factors are driving Factor Xa Inhibitors market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Factor Xa Inhibitors market opportunities vary by end market size?
- How does Factor Xa Inhibitors break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Factor Xa Inhibitors Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Factor Xa Inhibitors by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Factor Xa Inhibitors by Country/Region, 2021, 2025 & 2032
2.2 Factor Xa Inhibitors Segment by Type
2.2.1 Oral Drugs
2.2.2 Injections
2.2.3 Factor Xa Inhibitors Sales by Type
2.2.3.1 Global Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
2.2.3.2 Global Factor Xa Inhibitors Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Factor Xa Inhibitors Sale Price by Type (2021-2026)
2.3 Factor Xa Inhibitors Segment by Application
2.3.1 Deep Vein Thrombosis
2.3.2 Pulmonary Embolism
2.3.3 Atrial Fibrillation
2.3.4 Other
2.3.5 Factor Xa Inhibitors Sales by Application
2.3.5.1 Global Factor Xa Inhibitors Sale Market Share by Application (2021-2026)
2.3.5.2 Global Factor Xa Inhibitors Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Factor Xa Inhibitors Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Factor Xa Inhibitors Breakdown Data by Company
3.1.1 Global Factor Xa Inhibitors Annual Sales by Company (2021-2026)
3.1.2 Global Factor Xa Inhibitors Sales Market Share by Company (2021-2026)
3.2 Global Factor Xa Inhibitors Annual Revenue by Company (2021-2026)
3.2.1 Global Factor Xa Inhibitors Revenue by Company (2021-2026)
3.2.2 Global Factor Xa Inhibitors Revenue Market Share by Company (2021-2026)
3.3 Global Factor Xa Inhibitors Sale Price by Company
3.4 Key Manufacturers Factor Xa Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Factor Xa Inhibitors Product Location Distribution
3.4.2 Players Factor Xa Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR FACTOR XA INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic Factor Xa Inhibitors Market Size by Geographic Region (2021-2026)
4.1.1 Global Factor Xa Inhibitors Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Factor Xa Inhibitors Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Factor Xa Inhibitors Market Size by Country/Region (2021-2026)
4.2.1 Global Factor Xa Inhibitors Annual Sales by Country/Region (2021-2026)
4.2.2 Global Factor Xa Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas Factor Xa Inhibitors Sales Growth
4.4 APAC Factor Xa Inhibitors Sales Growth
4.5 Europe Factor Xa Inhibitors Sales Growth
4.6 Middle East & Africa Factor Xa Inhibitors Sales Growth
5 AMERICAS
5.1 Americas Factor Xa Inhibitors Sales by Country
5.1.1 Americas Factor Xa Inhibitors Sales by Country (2021-2026)
5.1.2 Americas Factor Xa Inhibitors Revenue by Country (2021-2026)
5.2 Americas Factor Xa Inhibitors Sales by Type (2021-2026)
5.3 Americas Factor Xa Inhibitors Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Factor Xa Inhibitors Sales by Region
6.1.1 APAC Factor Xa Inhibitors Sales by Region (2021-2026)
6.1.2 APAC Factor Xa Inhibitors Revenue by Region (2021-2026)
6.2 APAC Factor Xa Inhibitors Sales by Type (2021-2026)
6.3 APAC Factor Xa Inhibitors Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Factor Xa Inhibitors by Country
7.1.1 Europe Factor Xa Inhibitors Sales by Country (2021-2026)
7.1.2 Europe Factor Xa Inhibitors Revenue by Country (2021-2026)
7.2 Europe Factor Xa Inhibitors Sales by Type (2021-2026)
7.3 Europe Factor Xa Inhibitors Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Factor Xa Inhibitors by Country
8.1.1 Middle East & Africa Factor Xa Inhibitors Sales by Country (2021-2026)
8.1.2 Middle East & Africa Factor Xa Inhibitors Revenue by Country (2021-2026)
8.2 Middle East & Africa Factor Xa Inhibitors Sales by Type (2021-2026)
8.3 Middle East & Africa Factor Xa Inhibitors Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Factor Xa Inhibitors
10.3 Manufacturing Process Analysis of Factor Xa Inhibitors
10.4 Industry Chain Structure of Factor Xa Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Factor Xa Inhibitors Distributors
11.3 Factor Xa Inhibitors Customer
12 WORLD FORECAST REVIEW FOR FACTOR XA INHIBITORS BY GEOGRAPHIC REGION
12.1 Global Factor Xa Inhibitors Market Size Forecast by Region
12.1.1 Global Factor Xa Inhibitors Forecast by Region (2027-2032)
12.1.2 Global Factor Xa Inhibitors Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Factor Xa Inhibitors Forecast by Type (2027-2032)
12.7 Global Factor Xa Inhibitors Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Factor Xa Inhibitors Product Portfolios and Specifications
13.1.3 Pfizer Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Bristol Myers Squibb
13.2.1 Bristol Myers Squibb Company Information
13.2.2 Bristol Myers Squibb Factor Xa Inhibitors Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bristol Myers Squibb Main Business Overview
13.2.5 Bristol Myers Squibb Latest Developments
13.3 Daiichi Sankyo
13.3.1 Daiichi Sankyo Company Information
13.3.2 Daiichi Sankyo Factor Xa Inhibitors Product Portfolios and Specifications
13.3.3 Daiichi Sankyo Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Daiichi Sankyo Main Business Overview
13.3.5 Daiichi Sankyo Latest Developments
13.4 Janssen Pharmaceuticals
13.4.1 Janssen Pharmaceuticals Company Information
13.4.2 Janssen Pharmaceuticals Factor Xa Inhibitors Product Portfolios and Specifications
13.4.3 Janssen Pharmaceuticals Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Janssen Pharmaceuticals Main Business Overview
13.4.5 Janssen Pharmaceuticals Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Factor Xa Inhibitors Product Portfolios and Specifications
13.5.3 Bayer Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Viatris
13.6.1 Viatris Company Information
13.6.2 Viatris Factor Xa Inhibitors Product Portfolios and Specifications
13.6.3 Viatris Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Viatris Main Business Overview
13.6.5 Viatris Latest Developments
13.7 Dr. Reddy's Laboratories
13.7.1 Dr. Reddy's Laboratories Company Information
13.7.2 Dr. Reddy's Laboratories Factor Xa Inhibitors Product Portfolios and Specifications
13.7.3 Dr. Reddy's Laboratories Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Dr. Reddy's Laboratories Main Business Overview
13.7.5 Dr. Reddy's Laboratories Latest Developments
13.8 GlaxoSmithKline
13.8.1 GlaxoSmithKline Company Information
13.8.2 GlaxoSmithKline Factor Xa Inhibitors Product Portfolios and Specifications
13.8.3 GlaxoSmithKline Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 GlaxoSmithKline Main Business Overview
13.8.5 GlaxoSmithKline Latest Developments
13.9 Eugia Pharma
13.9.1 Eugia Pharma Company Information
13.9.2 Eugia Pharma Factor Xa Inhibitors Product Portfolios and Specifications
13.9.3 Eugia Pharma Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Eugia Pharma Main Business Overview
13.9.5 Eugia Pharma Latest Developments
13.10 Accord Healthcare
13.10.1 Accord Healthcare Company Information
13.10.2 Accord Healthcare Factor Xa Inhibitors Product Portfolios and Specifications
13.10.3 Accord Healthcare Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Accord Healthcare Main Business Overview
13.10.5 Accord Healthcare Latest Developments
13.11 Apotex
13.11.1 Apotex Company Information
13.11.2 Apotex Factor Xa Inhibitors Product Portfolios and Specifications
13.11.3 Apotex Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Apotex Main Business Overview
13.11.5 Apotex Latest Developments
13.12 Zydus
13.12.1 Zydus Company Information
13.12.2 Zydus Factor Xa Inhibitors Product Portfolios and Specifications
13.12.3 Zydus Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Zydus Main Business Overview
13.12.5 Zydus Latest Developments
13.13 Lupin
13.13.1 Lupin Company Information
13.13.2 Lupin Factor Xa Inhibitors Product Portfolios and Specifications
13.13.3 Lupin Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Lupin Main Business Overview
13.13.5 Lupin Latest Developments
13.14 Jiangsu Hengrui Pharmaceuticals
13.14.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.14.2 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Product Portfolios and Specifications
13.14.3 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.14.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.15 Cspc Ouyi Pharmaceutical
13.15.1 Cspc Ouyi Pharmaceutical Company Information
13.15.2 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.15.3 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Cspc Ouyi Pharmaceutical Main Business Overview
13.15.5 Cspc Ouyi Pharmaceutical Latest Developments
13.16 Zhejiang Hisun Pharmaceutical
13.16.1 Zhejiang Hisun Pharmaceutical Company Information
13.16.2 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.16.3 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Zhejiang Hisun Pharmaceutical Main Business Overview
13.16.5 Zhejiang Hisun Pharmaceutical Latest Developments
13.17 Hansoh Pharma
13.17.1 Hansoh Pharma Company Information
13.17.2 Hansoh Pharma Factor Xa Inhibitors Product Portfolios and Specifications
13.17.3 Hansoh Pharma Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Hansoh Pharma Main Business Overview
13.17.5 Hansoh Pharma Latest Developments
13.18 Chia Tai Tianqing Pharmaceutical
13.18.1 Chia Tai Tianqing Pharmaceutical Company Information
13.18.2 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.18.3 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.18.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.19 Shanghai Huilun Pharmaceutical
13.19.1 Shanghai Huilun Pharmaceutical Company Information
13.19.2 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.19.3 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Shanghai Huilun Pharmaceutical Main Business Overview
13.19.5 Shanghai Huilun Pharmaceutical Latest Developments
13.20 Qilu Pharmaceutical
13.20.1 Qilu Pharmaceutical Company Information
13.20.2 Qilu Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.20.3 Qilu Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Qilu Pharmaceutical Main Business Overview
13.20.5 Qilu Pharmaceutical Latest Developments
13.21 HEC Pharma
13.21.1 HEC Pharma Company Information
13.21.2 HEC Pharma Factor Xa Inhibitors Product Portfolios and Specifications
13.21.3 HEC Pharma Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 HEC Pharma Main Business Overview
13.21.5 HEC Pharma Latest Developments
13.22 BrightGene
13.22.1 BrightGene Company Information
13.22.2 BrightGene Factor Xa Inhibitors Product Portfolios and Specifications
13.22.3 BrightGene Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 BrightGene Main Business Overview
13.22.5 BrightGene Latest Developments
13.23 Kelun Pharmaceutical
13.23.1 Kelun Pharmaceutical Company Information
13.23.2 Kelun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.23.3 Kelun Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Kelun Pharmaceutical Main Business Overview
13.23.5 Kelun Pharmaceutical Latest Developments
13.24 Nanjing King-Friend Biochemical Pharmaceutical
13.24.1 Nanjing King-Friend Biochemical Pharmaceutical Company Information
13.24.2 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.24.3 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Nanjing King-Friend Biochemical Pharmaceutical Main Business Overview
13.24.5 Nanjing King-Friend Biochemical Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Factor Xa Inhibitors Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Factor Xa Inhibitors by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Factor Xa Inhibitors by Country/Region, 2021, 2025 & 2032
2.2 Factor Xa Inhibitors Segment by Type
2.2.1 Oral Drugs
2.2.2 Injections
2.2.3 Factor Xa Inhibitors Sales by Type
2.2.3.1 Global Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
2.2.3.2 Global Factor Xa Inhibitors Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Factor Xa Inhibitors Sale Price by Type (2021-2026)
2.3 Factor Xa Inhibitors Segment by Application
2.3.1 Deep Vein Thrombosis
2.3.2 Pulmonary Embolism
2.3.3 Atrial Fibrillation
2.3.4 Other
2.3.5 Factor Xa Inhibitors Sales by Application
2.3.5.1 Global Factor Xa Inhibitors Sale Market Share by Application (2021-2026)
2.3.5.2 Global Factor Xa Inhibitors Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Factor Xa Inhibitors Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Factor Xa Inhibitors Breakdown Data by Company
3.1.1 Global Factor Xa Inhibitors Annual Sales by Company (2021-2026)
3.1.2 Global Factor Xa Inhibitors Sales Market Share by Company (2021-2026)
3.2 Global Factor Xa Inhibitors Annual Revenue by Company (2021-2026)
3.2.1 Global Factor Xa Inhibitors Revenue by Company (2021-2026)
3.2.2 Global Factor Xa Inhibitors Revenue Market Share by Company (2021-2026)
3.3 Global Factor Xa Inhibitors Sale Price by Company
3.4 Key Manufacturers Factor Xa Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Factor Xa Inhibitors Product Location Distribution
3.4.2 Players Factor Xa Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR FACTOR XA INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic Factor Xa Inhibitors Market Size by Geographic Region (2021-2026)
4.1.1 Global Factor Xa Inhibitors Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Factor Xa Inhibitors Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Factor Xa Inhibitors Market Size by Country/Region (2021-2026)
4.2.1 Global Factor Xa Inhibitors Annual Sales by Country/Region (2021-2026)
4.2.2 Global Factor Xa Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas Factor Xa Inhibitors Sales Growth
4.4 APAC Factor Xa Inhibitors Sales Growth
4.5 Europe Factor Xa Inhibitors Sales Growth
4.6 Middle East & Africa Factor Xa Inhibitors Sales Growth
5 AMERICAS
5.1 Americas Factor Xa Inhibitors Sales by Country
5.1.1 Americas Factor Xa Inhibitors Sales by Country (2021-2026)
5.1.2 Americas Factor Xa Inhibitors Revenue by Country (2021-2026)
5.2 Americas Factor Xa Inhibitors Sales by Type (2021-2026)
5.3 Americas Factor Xa Inhibitors Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Factor Xa Inhibitors Sales by Region
6.1.1 APAC Factor Xa Inhibitors Sales by Region (2021-2026)
6.1.2 APAC Factor Xa Inhibitors Revenue by Region (2021-2026)
6.2 APAC Factor Xa Inhibitors Sales by Type (2021-2026)
6.3 APAC Factor Xa Inhibitors Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Factor Xa Inhibitors by Country
7.1.1 Europe Factor Xa Inhibitors Sales by Country (2021-2026)
7.1.2 Europe Factor Xa Inhibitors Revenue by Country (2021-2026)
7.2 Europe Factor Xa Inhibitors Sales by Type (2021-2026)
7.3 Europe Factor Xa Inhibitors Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Factor Xa Inhibitors by Country
8.1.1 Middle East & Africa Factor Xa Inhibitors Sales by Country (2021-2026)
8.1.2 Middle East & Africa Factor Xa Inhibitors Revenue by Country (2021-2026)
8.2 Middle East & Africa Factor Xa Inhibitors Sales by Type (2021-2026)
8.3 Middle East & Africa Factor Xa Inhibitors Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Factor Xa Inhibitors
10.3 Manufacturing Process Analysis of Factor Xa Inhibitors
10.4 Industry Chain Structure of Factor Xa Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Factor Xa Inhibitors Distributors
11.3 Factor Xa Inhibitors Customer
12 WORLD FORECAST REVIEW FOR FACTOR XA INHIBITORS BY GEOGRAPHIC REGION
12.1 Global Factor Xa Inhibitors Market Size Forecast by Region
12.1.1 Global Factor Xa Inhibitors Forecast by Region (2027-2032)
12.1.2 Global Factor Xa Inhibitors Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Factor Xa Inhibitors Forecast by Type (2027-2032)
12.7 Global Factor Xa Inhibitors Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Factor Xa Inhibitors Product Portfolios and Specifications
13.1.3 Pfizer Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Bristol Myers Squibb
13.2.1 Bristol Myers Squibb Company Information
13.2.2 Bristol Myers Squibb Factor Xa Inhibitors Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bristol Myers Squibb Main Business Overview
13.2.5 Bristol Myers Squibb Latest Developments
13.3 Daiichi Sankyo
13.3.1 Daiichi Sankyo Company Information
13.3.2 Daiichi Sankyo Factor Xa Inhibitors Product Portfolios and Specifications
13.3.3 Daiichi Sankyo Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Daiichi Sankyo Main Business Overview
13.3.5 Daiichi Sankyo Latest Developments
13.4 Janssen Pharmaceuticals
13.4.1 Janssen Pharmaceuticals Company Information
13.4.2 Janssen Pharmaceuticals Factor Xa Inhibitors Product Portfolios and Specifications
13.4.3 Janssen Pharmaceuticals Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Janssen Pharmaceuticals Main Business Overview
13.4.5 Janssen Pharmaceuticals Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Factor Xa Inhibitors Product Portfolios and Specifications
13.5.3 Bayer Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Viatris
13.6.1 Viatris Company Information
13.6.2 Viatris Factor Xa Inhibitors Product Portfolios and Specifications
13.6.3 Viatris Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Viatris Main Business Overview
13.6.5 Viatris Latest Developments
13.7 Dr. Reddy's Laboratories
13.7.1 Dr. Reddy's Laboratories Company Information
13.7.2 Dr. Reddy's Laboratories Factor Xa Inhibitors Product Portfolios and Specifications
13.7.3 Dr. Reddy's Laboratories Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Dr. Reddy's Laboratories Main Business Overview
13.7.5 Dr. Reddy's Laboratories Latest Developments
13.8 GlaxoSmithKline
13.8.1 GlaxoSmithKline Company Information
13.8.2 GlaxoSmithKline Factor Xa Inhibitors Product Portfolios and Specifications
13.8.3 GlaxoSmithKline Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 GlaxoSmithKline Main Business Overview
13.8.5 GlaxoSmithKline Latest Developments
13.9 Eugia Pharma
13.9.1 Eugia Pharma Company Information
13.9.2 Eugia Pharma Factor Xa Inhibitors Product Portfolios and Specifications
13.9.3 Eugia Pharma Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Eugia Pharma Main Business Overview
13.9.5 Eugia Pharma Latest Developments
13.10 Accord Healthcare
13.10.1 Accord Healthcare Company Information
13.10.2 Accord Healthcare Factor Xa Inhibitors Product Portfolios and Specifications
13.10.3 Accord Healthcare Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Accord Healthcare Main Business Overview
13.10.5 Accord Healthcare Latest Developments
13.11 Apotex
13.11.1 Apotex Company Information
13.11.2 Apotex Factor Xa Inhibitors Product Portfolios and Specifications
13.11.3 Apotex Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Apotex Main Business Overview
13.11.5 Apotex Latest Developments
13.12 Zydus
13.12.1 Zydus Company Information
13.12.2 Zydus Factor Xa Inhibitors Product Portfolios and Specifications
13.12.3 Zydus Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Zydus Main Business Overview
13.12.5 Zydus Latest Developments
13.13 Lupin
13.13.1 Lupin Company Information
13.13.2 Lupin Factor Xa Inhibitors Product Portfolios and Specifications
13.13.3 Lupin Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Lupin Main Business Overview
13.13.5 Lupin Latest Developments
13.14 Jiangsu Hengrui Pharmaceuticals
13.14.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.14.2 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Product Portfolios and Specifications
13.14.3 Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.14.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.15 Cspc Ouyi Pharmaceutical
13.15.1 Cspc Ouyi Pharmaceutical Company Information
13.15.2 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.15.3 Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Cspc Ouyi Pharmaceutical Main Business Overview
13.15.5 Cspc Ouyi Pharmaceutical Latest Developments
13.16 Zhejiang Hisun Pharmaceutical
13.16.1 Zhejiang Hisun Pharmaceutical Company Information
13.16.2 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.16.3 Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Zhejiang Hisun Pharmaceutical Main Business Overview
13.16.5 Zhejiang Hisun Pharmaceutical Latest Developments
13.17 Hansoh Pharma
13.17.1 Hansoh Pharma Company Information
13.17.2 Hansoh Pharma Factor Xa Inhibitors Product Portfolios and Specifications
13.17.3 Hansoh Pharma Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Hansoh Pharma Main Business Overview
13.17.5 Hansoh Pharma Latest Developments
13.18 Chia Tai Tianqing Pharmaceutical
13.18.1 Chia Tai Tianqing Pharmaceutical Company Information
13.18.2 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.18.3 Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.18.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.19 Shanghai Huilun Pharmaceutical
13.19.1 Shanghai Huilun Pharmaceutical Company Information
13.19.2 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.19.3 Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Shanghai Huilun Pharmaceutical Main Business Overview
13.19.5 Shanghai Huilun Pharmaceutical Latest Developments
13.20 Qilu Pharmaceutical
13.20.1 Qilu Pharmaceutical Company Information
13.20.2 Qilu Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.20.3 Qilu Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Qilu Pharmaceutical Main Business Overview
13.20.5 Qilu Pharmaceutical Latest Developments
13.21 HEC Pharma
13.21.1 HEC Pharma Company Information
13.21.2 HEC Pharma Factor Xa Inhibitors Product Portfolios and Specifications
13.21.3 HEC Pharma Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 HEC Pharma Main Business Overview
13.21.5 HEC Pharma Latest Developments
13.22 BrightGene
13.22.1 BrightGene Company Information
13.22.2 BrightGene Factor Xa Inhibitors Product Portfolios and Specifications
13.22.3 BrightGene Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 BrightGene Main Business Overview
13.22.5 BrightGene Latest Developments
13.23 Kelun Pharmaceutical
13.23.1 Kelun Pharmaceutical Company Information
13.23.2 Kelun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.23.3 Kelun Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Kelun Pharmaceutical Main Business Overview
13.23.5 Kelun Pharmaceutical Latest Developments
13.24 Nanjing King-Friend Biochemical Pharmaceutical
13.24.1 Nanjing King-Friend Biochemical Pharmaceutical Company Information
13.24.2 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
13.24.3 Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Nanjing King-Friend Biochemical Pharmaceutical Main Business Overview
13.24.5 Nanjing King-Friend Biochemical Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Factor Xa Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Factor Xa Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oral Drugs
Table 4. Major Players of Injections
Table 5. Global Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 6. Global Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Table 7. Global Factor Xa Inhibitors Revenue by Type (2021-2026) & ($ million)
Table 8. Global Factor Xa Inhibitors Revenue Market Share by Type (2021-2026)
Table 9. Global Factor Xa Inhibitors Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Factor Xa Inhibitors Sale by Application (2021-2026) & (K Units)
Table 11. Global Factor Xa Inhibitors Sale Market Share by Application (2021-2026)
Table 12. Global Factor Xa Inhibitors Revenue by Application (2021-2026) & ($ million)
Table 13. Global Factor Xa Inhibitors Revenue Market Share by Application (2021-2026)
Table 14. Global Factor Xa Inhibitors Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Factor Xa Inhibitors Sales by Company (2021-2026) & (K Units)
Table 16. Global Factor Xa Inhibitors Sales Market Share by Company (2021-2026)
Table 17. Global Factor Xa Inhibitors Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Factor Xa Inhibitors Revenue Market Share by Company (2021-2026)
Table 19. Global Factor Xa Inhibitors Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Factor Xa Inhibitors Producing Area Distribution and Sales Area
Table 21. Players Factor Xa Inhibitors Products Offered
Table 22. Factor Xa Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Factor Xa Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Factor Xa Inhibitors Sales Market Share Geographic Region (2021-2026)
Table 27. Global Factor Xa Inhibitors Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Factor Xa Inhibitors Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Factor Xa Inhibitors Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Factor Xa Inhibitors Sales Market Share by Country/Region (2021-2026)
Table 31. Global Factor Xa Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Factor Xa Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 34. Americas Factor Xa Inhibitors Sales Market Share by Country (2021-2026)
Table 35. Americas Factor Xa Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 37. Americas Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 38. APAC Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units)
Table 39. APAC Factor Xa Inhibitors Sales Market Share by Region (2021-2026)
Table 40. APAC Factor Xa Inhibitors Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 42. APAC Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 43. Europe Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 44. Europe Factor Xa Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 46. Europe Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Factor Xa Inhibitors
Table 52. Key Market Challenges & Risks of Factor Xa Inhibitors
Table 53. Key Industry Trends of Factor Xa Inhibitors
Table 54. Factor Xa Inhibitors Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Factor Xa Inhibitors Distributors List
Table 57. Factor Xa Inhibitors Customer List
Table 58. Global Factor Xa Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Factor Xa Inhibitors Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Factor Xa Inhibitors Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Factor Xa Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Factor Xa Inhibitors Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Factor Xa Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Factor Xa Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Factor Xa Inhibitors Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Factor Xa Inhibitors Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Factor Xa Inhibitors Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Factor Xa Inhibitors Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Pfizer Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 73. Pfizer Factor Xa Inhibitors Product Portfolios and Specifications
Table 74. Pfizer Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Pfizer Main Business
Table 76. Pfizer Latest Developments
Table 77. Bristol Myers Squibb Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 78. Bristol Myers Squibb Factor Xa Inhibitors Product Portfolios and Specifications
Table 79. Bristol Myers Squibb Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Bristol Myers Squibb Main Business
Table 81. Bristol Myers Squibb Latest Developments
Table 82. Daiichi Sankyo Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 83. Daiichi Sankyo Factor Xa Inhibitors Product Portfolios and Specifications
Table 84. Daiichi Sankyo Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Daiichi Sankyo Main Business
Table 86. Daiichi Sankyo Latest Developments
Table 87. Janssen Pharmaceuticals Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 88. Janssen Pharmaceuticals Factor Xa Inhibitors Product Portfolios and Specifications
Table 89. Janssen Pharmaceuticals Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Janssen Pharmaceuticals Main Business
Table 91. Janssen Pharmaceuticals Latest Developments
Table 92. Bayer Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 93. Bayer Factor Xa Inhibitors Product Portfolios and Specifications
Table 94. Bayer Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Bayer Main Business
Table 96. Bayer Latest Developments
Table 97. Viatris Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 98. Viatris Factor Xa Inhibitors Product Portfolios and Specifications
Table 99. Viatris Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Viatris Main Business
Table 101. Viatris Latest Developments
Table 102. Dr. Reddy's Laboratories Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 103. Dr. Reddy's Laboratories Factor Xa Inhibitors Product Portfolios and Specifications
Table 104. Dr. Reddy's Laboratories Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Dr. Reddy's Laboratories Main Business
Table 106. Dr. Reddy's Laboratories Latest Developments
Table 107. GlaxoSmithKline Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 108. GlaxoSmithKline Factor Xa Inhibitors Product Portfolios and Specifications
Table 109. GlaxoSmithKline Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. GlaxoSmithKline Main Business
Table 111. GlaxoSmithKline Latest Developments
Table 112. Eugia Pharma Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 113. Eugia Pharma Factor Xa Inhibitors Product Portfolios and Specifications
Table 114. Eugia Pharma Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Eugia Pharma Main Business
Table 116. Eugia Pharma Latest Developments
Table 117. Accord Healthcare Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 118. Accord Healthcare Factor Xa Inhibitors Product Portfolios and Specifications
Table 119. Accord Healthcare Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Accord Healthcare Main Business
Table 121. Accord Healthcare Latest Developments
Table 122. Apotex Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 123. Apotex Factor Xa Inhibitors Product Portfolios and Specifications
Table 124. Apotex Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Apotex Main Business
Table 126. Apotex Latest Developments
Table 127. Zydus Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 128. Zydus Factor Xa Inhibitors Product Portfolios and Specifications
Table 129. Zydus Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Zydus Main Business
Table 131. Zydus Latest Developments
Table 132. Lupin Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 133. Lupin Factor Xa Inhibitors Product Portfolios and Specifications
Table 134. Lupin Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Lupin Main Business
Table 136. Lupin Latest Developments
Table 137. Jiangsu Hengrui Pharmaceuticals Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 138. Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Product Portfolios and Specifications
Table 139. Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Jiangsu Hengrui Pharmaceuticals Main Business
Table 141. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 142. Cspc Ouyi Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 143. Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 144. Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Cspc Ouyi Pharmaceutical Main Business
Table 146. Cspc Ouyi Pharmaceutical Latest Developments
Table 147. Zhejiang Hisun Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 148. Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 149. Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. Zhejiang Hisun Pharmaceutical Main Business
Table 151. Zhejiang Hisun Pharmaceutical Latest Developments
Table 152. Hansoh Pharma Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 153. Hansoh Pharma Factor Xa Inhibitors Product Portfolios and Specifications
Table 154. Hansoh Pharma Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 155. Hansoh Pharma Main Business
Table 156. Hansoh Pharma Latest Developments
Table 157. Chia Tai Tianqing Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 158. Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 159. Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 160. Chia Tai Tianqing Pharmaceutical Main Business
Table 161. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 162. Shanghai Huilun Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 163. Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 164. Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 165. Shanghai Huilun Pharmaceutical Main Business
Table 166. Shanghai Huilun Pharmaceutical Latest Developments
Table 167. Qilu Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 168. Qilu Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 169. Qilu Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 170. Qilu Pharmaceutical Main Business
Table 171. Qilu Pharmaceutical Latest Developments
Table 172. HEC Pharma Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 173. HEC Pharma Factor Xa Inhibitors Product Portfolios and Specifications
Table 174. HEC Pharma Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 175. HEC Pharma Main Business
Table 176. HEC Pharma Latest Developments
Table 177. BrightGene Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 178. BrightGene Factor Xa Inhibitors Product Portfolios and Specifications
Table 179. BrightGene Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 180. BrightGene Main Business
Table 181. BrightGene Latest Developments
Table 182. Kelun Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 183. Kelun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 184. Kelun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 185. Kelun Pharmaceutical Main Business
Table 186. Kelun Pharmaceutical Latest Developments
Table 187. Nanjing King-Friend Biochemical Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 188. Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 189. Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 190. Nanjing King-Friend Biochemical Pharmaceutical Main Business
Table 191. Nanjing King-Friend Biochemical Pharmaceutical Latest Developments
Table 1. Factor Xa Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Factor Xa Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oral Drugs
Table 4. Major Players of Injections
Table 5. Global Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 6. Global Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Table 7. Global Factor Xa Inhibitors Revenue by Type (2021-2026) & ($ million)
Table 8. Global Factor Xa Inhibitors Revenue Market Share by Type (2021-2026)
Table 9. Global Factor Xa Inhibitors Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Factor Xa Inhibitors Sale by Application (2021-2026) & (K Units)
Table 11. Global Factor Xa Inhibitors Sale Market Share by Application (2021-2026)
Table 12. Global Factor Xa Inhibitors Revenue by Application (2021-2026) & ($ million)
Table 13. Global Factor Xa Inhibitors Revenue Market Share by Application (2021-2026)
Table 14. Global Factor Xa Inhibitors Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Factor Xa Inhibitors Sales by Company (2021-2026) & (K Units)
Table 16. Global Factor Xa Inhibitors Sales Market Share by Company (2021-2026)
Table 17. Global Factor Xa Inhibitors Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Factor Xa Inhibitors Revenue Market Share by Company (2021-2026)
Table 19. Global Factor Xa Inhibitors Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Factor Xa Inhibitors Producing Area Distribution and Sales Area
Table 21. Players Factor Xa Inhibitors Products Offered
Table 22. Factor Xa Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Factor Xa Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Factor Xa Inhibitors Sales Market Share Geographic Region (2021-2026)
Table 27. Global Factor Xa Inhibitors Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Factor Xa Inhibitors Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Factor Xa Inhibitors Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Factor Xa Inhibitors Sales Market Share by Country/Region (2021-2026)
Table 31. Global Factor Xa Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Factor Xa Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 34. Americas Factor Xa Inhibitors Sales Market Share by Country (2021-2026)
Table 35. Americas Factor Xa Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 37. Americas Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 38. APAC Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units)
Table 39. APAC Factor Xa Inhibitors Sales Market Share by Region (2021-2026)
Table 40. APAC Factor Xa Inhibitors Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 42. APAC Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 43. Europe Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 44. Europe Factor Xa Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 46. Europe Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Factor Xa Inhibitors
Table 52. Key Market Challenges & Risks of Factor Xa Inhibitors
Table 53. Key Industry Trends of Factor Xa Inhibitors
Table 54. Factor Xa Inhibitors Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Factor Xa Inhibitors Distributors List
Table 57. Factor Xa Inhibitors Customer List
Table 58. Global Factor Xa Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Factor Xa Inhibitors Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Factor Xa Inhibitors Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Factor Xa Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Factor Xa Inhibitors Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Factor Xa Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Factor Xa Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Factor Xa Inhibitors Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Factor Xa Inhibitors Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Factor Xa Inhibitors Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Factor Xa Inhibitors Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Pfizer Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 73. Pfizer Factor Xa Inhibitors Product Portfolios and Specifications
Table 74. Pfizer Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Pfizer Main Business
Table 76. Pfizer Latest Developments
Table 77. Bristol Myers Squibb Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 78. Bristol Myers Squibb Factor Xa Inhibitors Product Portfolios and Specifications
Table 79. Bristol Myers Squibb Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Bristol Myers Squibb Main Business
Table 81. Bristol Myers Squibb Latest Developments
Table 82. Daiichi Sankyo Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 83. Daiichi Sankyo Factor Xa Inhibitors Product Portfolios and Specifications
Table 84. Daiichi Sankyo Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Daiichi Sankyo Main Business
Table 86. Daiichi Sankyo Latest Developments
Table 87. Janssen Pharmaceuticals Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 88. Janssen Pharmaceuticals Factor Xa Inhibitors Product Portfolios and Specifications
Table 89. Janssen Pharmaceuticals Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Janssen Pharmaceuticals Main Business
Table 91. Janssen Pharmaceuticals Latest Developments
Table 92. Bayer Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 93. Bayer Factor Xa Inhibitors Product Portfolios and Specifications
Table 94. Bayer Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Bayer Main Business
Table 96. Bayer Latest Developments
Table 97. Viatris Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 98. Viatris Factor Xa Inhibitors Product Portfolios and Specifications
Table 99. Viatris Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Viatris Main Business
Table 101. Viatris Latest Developments
Table 102. Dr. Reddy's Laboratories Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 103. Dr. Reddy's Laboratories Factor Xa Inhibitors Product Portfolios and Specifications
Table 104. Dr. Reddy's Laboratories Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Dr. Reddy's Laboratories Main Business
Table 106. Dr. Reddy's Laboratories Latest Developments
Table 107. GlaxoSmithKline Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 108. GlaxoSmithKline Factor Xa Inhibitors Product Portfolios and Specifications
Table 109. GlaxoSmithKline Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. GlaxoSmithKline Main Business
Table 111. GlaxoSmithKline Latest Developments
Table 112. Eugia Pharma Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 113. Eugia Pharma Factor Xa Inhibitors Product Portfolios and Specifications
Table 114. Eugia Pharma Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Eugia Pharma Main Business
Table 116. Eugia Pharma Latest Developments
Table 117. Accord Healthcare Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 118. Accord Healthcare Factor Xa Inhibitors Product Portfolios and Specifications
Table 119. Accord Healthcare Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Accord Healthcare Main Business
Table 121. Accord Healthcare Latest Developments
Table 122. Apotex Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 123. Apotex Factor Xa Inhibitors Product Portfolios and Specifications
Table 124. Apotex Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Apotex Main Business
Table 126. Apotex Latest Developments
Table 127. Zydus Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 128. Zydus Factor Xa Inhibitors Product Portfolios and Specifications
Table 129. Zydus Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Zydus Main Business
Table 131. Zydus Latest Developments
Table 132. Lupin Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 133. Lupin Factor Xa Inhibitors Product Portfolios and Specifications
Table 134. Lupin Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Lupin Main Business
Table 136. Lupin Latest Developments
Table 137. Jiangsu Hengrui Pharmaceuticals Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 138. Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Product Portfolios and Specifications
Table 139. Jiangsu Hengrui Pharmaceuticals Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Jiangsu Hengrui Pharmaceuticals Main Business
Table 141. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 142. Cspc Ouyi Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 143. Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 144. Cspc Ouyi Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Cspc Ouyi Pharmaceutical Main Business
Table 146. Cspc Ouyi Pharmaceutical Latest Developments
Table 147. Zhejiang Hisun Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 148. Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 149. Zhejiang Hisun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. Zhejiang Hisun Pharmaceutical Main Business
Table 151. Zhejiang Hisun Pharmaceutical Latest Developments
Table 152. Hansoh Pharma Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 153. Hansoh Pharma Factor Xa Inhibitors Product Portfolios and Specifications
Table 154. Hansoh Pharma Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 155. Hansoh Pharma Main Business
Table 156. Hansoh Pharma Latest Developments
Table 157. Chia Tai Tianqing Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 158. Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 159. Chia Tai Tianqing Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 160. Chia Tai Tianqing Pharmaceutical Main Business
Table 161. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 162. Shanghai Huilun Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 163. Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 164. Shanghai Huilun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 165. Shanghai Huilun Pharmaceutical Main Business
Table 166. Shanghai Huilun Pharmaceutical Latest Developments
Table 167. Qilu Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 168. Qilu Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 169. Qilu Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 170. Qilu Pharmaceutical Main Business
Table 171. Qilu Pharmaceutical Latest Developments
Table 172. HEC Pharma Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 173. HEC Pharma Factor Xa Inhibitors Product Portfolios and Specifications
Table 174. HEC Pharma Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 175. HEC Pharma Main Business
Table 176. HEC Pharma Latest Developments
Table 177. BrightGene Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 178. BrightGene Factor Xa Inhibitors Product Portfolios and Specifications
Table 179. BrightGene Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 180. BrightGene Main Business
Table 181. BrightGene Latest Developments
Table 182. Kelun Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 183. Kelun Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 184. Kelun Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 185. Kelun Pharmaceutical Main Business
Table 186. Kelun Pharmaceutical Latest Developments
Table 187. Nanjing King-Friend Biochemical Pharmaceutical Basic Information, Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 188. Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Product Portfolios and Specifications
Table 189. Nanjing King-Friend Biochemical Pharmaceutical Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 190. Nanjing King-Friend Biochemical Pharmaceutical Main Business
Table 191. Nanjing King-Friend Biochemical Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Factor Xa Inhibitors
Figure 2. Factor Xa Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Factor Xa Inhibitors Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Factor Xa Inhibitors Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Factor Xa Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Factor Xa Inhibitors Sales Market Share by Country/Region (2025)
Figure 10. Factor Xa Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oral Drugs
Figure 12. Product Picture of Injections
Figure 13. Global Factor Xa Inhibitors Sales Market Share by Type in 2026
Figure 14. Global Factor Xa Inhibitors Revenue Market Share by Type (2021-2026)
Figure 15. Factor Xa Inhibitors Consumed in Deep Vein Thrombosis
Figure 16. Global Factor Xa Inhibitors Market: Deep Vein Thrombosis (2021-2026) & (K Units)
Figure 17. Factor Xa Inhibitors Consumed in Pulmonary Embolism
Figure 18. Global Factor Xa Inhibitors Market: Pulmonary Embolism (2021-2026) & (K Units)
Figure 19. Factor Xa Inhibitors Consumed in Atrial Fibrillation
Figure 20. Global Factor Xa Inhibitors Market: Atrial Fibrillation (2021-2026) & (K Units)
Figure 21. Factor Xa Inhibitors Consumed in Other
Figure 22. Global Factor Xa Inhibitors Market: Other (2021-2026) & (K Units)
Figure 23. Global Factor Xa Inhibitors Sale Market Share by Application (2025)
Figure 24. Global Factor Xa Inhibitors Revenue Market Share by Application in 2026
Figure 25. Factor Xa Inhibitors Sales by Company in 2026 (K Units)
Figure 26. Global Factor Xa Inhibitors Sales Market Share by Company in 2026
Figure 27. Factor Xa Inhibitors Revenue by Company in 2026 ($ millions)
Figure 28. Global Factor Xa Inhibitors Revenue Market Share by Company in 2026
Figure 29. Global Factor Xa Inhibitors Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Factor Xa Inhibitors Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 32. Americas Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 33. APAC Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 34. APAC Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 35. Europe Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 36. Europe Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 39. Americas Factor Xa Inhibitors Sales Market Share by Country in 2026
Figure 40. Americas Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Figure 41. Americas Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 42. Americas Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 43. United States Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Factor Xa Inhibitors Sales Market Share by Region in 2026
Figure 48. APAC Factor Xa Inhibitors Revenue Market Share by Region (2021-2026)
Figure 49. APAC Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 50. APAC Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 51. China Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 55. India Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Factor Xa Inhibitors Sales Market Share by Country in 2026
Figure 59. Europe Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Figure 60. Europe Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 61. Europe Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 62. Germany Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 63. France Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Factor Xa Inhibitors Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 70. Egypt Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Factor Xa Inhibitors in 2026
Figure 76. Manufacturing Process Analysis of Factor Xa Inhibitors
Figure 77. Industry Chain Structure of Factor Xa Inhibitors
Figure 78. Channels of Distribution
Figure 79. Global Factor Xa Inhibitors Sales Market Forecast by Region (2027-2032)
Figure 80. Global Factor Xa Inhibitors Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Factor Xa Inhibitors Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Factor Xa Inhibitors Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Factor Xa Inhibitors Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Factor Xa Inhibitors Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Factor Xa Inhibitors
Figure 2. Factor Xa Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Factor Xa Inhibitors Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Factor Xa Inhibitors Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Factor Xa Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Factor Xa Inhibitors Sales Market Share by Country/Region (2025)
Figure 10. Factor Xa Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oral Drugs
Figure 12. Product Picture of Injections
Figure 13. Global Factor Xa Inhibitors Sales Market Share by Type in 2026
Figure 14. Global Factor Xa Inhibitors Revenue Market Share by Type (2021-2026)
Figure 15. Factor Xa Inhibitors Consumed in Deep Vein Thrombosis
Figure 16. Global Factor Xa Inhibitors Market: Deep Vein Thrombosis (2021-2026) & (K Units)
Figure 17. Factor Xa Inhibitors Consumed in Pulmonary Embolism
Figure 18. Global Factor Xa Inhibitors Market: Pulmonary Embolism (2021-2026) & (K Units)
Figure 19. Factor Xa Inhibitors Consumed in Atrial Fibrillation
Figure 20. Global Factor Xa Inhibitors Market: Atrial Fibrillation (2021-2026) & (K Units)
Figure 21. Factor Xa Inhibitors Consumed in Other
Figure 22. Global Factor Xa Inhibitors Market: Other (2021-2026) & (K Units)
Figure 23. Global Factor Xa Inhibitors Sale Market Share by Application (2025)
Figure 24. Global Factor Xa Inhibitors Revenue Market Share by Application in 2026
Figure 25. Factor Xa Inhibitors Sales by Company in 2026 (K Units)
Figure 26. Global Factor Xa Inhibitors Sales Market Share by Company in 2026
Figure 27. Factor Xa Inhibitors Revenue by Company in 2026 ($ millions)
Figure 28. Global Factor Xa Inhibitors Revenue Market Share by Company in 2026
Figure 29. Global Factor Xa Inhibitors Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Factor Xa Inhibitors Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 32. Americas Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 33. APAC Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 34. APAC Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 35. Europe Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 36. Europe Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 39. Americas Factor Xa Inhibitors Sales Market Share by Country in 2026
Figure 40. Americas Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Figure 41. Americas Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 42. Americas Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 43. United States Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Factor Xa Inhibitors Sales Market Share by Region in 2026
Figure 48. APAC Factor Xa Inhibitors Revenue Market Share by Region (2021-2026)
Figure 49. APAC Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 50. APAC Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 51. China Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 55. India Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Factor Xa Inhibitors Sales Market Share by Country in 2026
Figure 59. Europe Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Figure 60. Europe Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 61. Europe Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 62. Germany Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 63. France Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Factor Xa Inhibitors Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 70. Egypt Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Factor Xa Inhibitors in 2026
Figure 76. Manufacturing Process Analysis of Factor Xa Inhibitors
Figure 77. Industry Chain Structure of Factor Xa Inhibitors
Figure 78. Channels of Distribution
Figure 79. Global Factor Xa Inhibitors Sales Market Forecast by Region (2027-2032)
Figure 80. Global Factor Xa Inhibitors Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Factor Xa Inhibitors Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Factor Xa Inhibitors Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Factor Xa Inhibitors Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Factor Xa Inhibitors Revenue Market Share Forecast by Application (2027-2032)
